WT1 and Miyoshi myopathy: Currently, DC loading with the Survivin antigen using an adeno-associated vector (clinicaltrials.gov identifier: NCT02851056) and DC-based therapy with Wilms Tumor 1 Gene (WT1) mRNA (clinicaltrials.gov identifier: NCT00965224) are being translated to the clinic for patients with MM.